Spondyloarthritis Research and Treatment Network
Nonprofit profile at a glance
- EIN
- 464072112
- IRS 990 coverage
- 2015–2025
- Forms available
- Form 990 2025
- Location
- Portland, OR, USA
- Phone
- 3606002170
- Rating
- 84
- Verdict
- STRONG
- Rating confidence
- Moderate
- Sector
- Arthritis
Reported finances
- Revenue
- $62,180
- Expenses
- $397,610
- Assets
- $3,912,478
- Liabilities
- $0
Source: IRS Form 990. Selected filing: tax year 2025. Amounts in USD.
Leadership & pay
12 people listed
Executive titles in this filing
- LISA SPIEGEL (EXECUTIVE DIRECTOR)
People named in this filing
- MATTHEW STOLL PHD MD (CHAIR)
- JOERG ERMANN MD (IMMEDIATE PAST CHAIR)
- IGNACIO GARCIA-VALLARDES MD (DIRECTOR)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
The mission of spartan is to foster research and education in spondyloarthritis in the united states. Spartan members accomplish this mission by engaging in specific research projects and through an annual meeting, which highlights important education and research programs.
What it reported doing in 2025
Spartan annual meetingspartan holds an annual meeting to highlight advances in spondyloarthritis research and treatment and encourage post-doctoral fellows to engage in the spartan mission of fostering research and education in the field of spondyloarthritis (spa). The research and education meeting is also an opportunity to bring together expert, dedicated researchers to identify and address unmet needs in the field of spa research and therapy. Presenters in the scientific sessions are the prominent international experts in their fields. The spondyloarthritis review course is a pre-meeting workshop for rheumatology fellows, apps, and other trainees. We conducted an ultrasound workshop attended by more than 75 learners.spartan research projectsbasis (biomarkers in axial spondyloarthritis investigative study) the primary objective is to establish a well-characterized biobank for axspa and identify a diagnostic biomarker(s) utilizing a cross-sectional study of individuals within the spectrum of axspa. The basis steering committee is collaborating with industry partners and intends to launch the program in 2025.
Operating model
- Revenue model
- Donor-supported. 89% of the money available for current operations came from contributions and gifts.
- Distribution model
- Grant intermediary. The nonprofit sent 78% of its reported program spending out as grants.
The verdict
STRONG - A large share of available resources goes toward mission work and the filed numbers largely add up. Expenses are high relative to revenue and revenue has declined or grown slowly.
Rating breakdown
- Financial Efficiency: 89
- Transparency & Controls: 88
- Accountability: 88
- Sustainability: 37
- Growth: 60
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 100%; rating input score 100
- Program expense ratio: 99.6%; rating input score 100
- Fundraising efficiency: Limited
Transparency & Controls
- Consistency checks: 90.9%; rating input score 91; 19th percentile among comparable filings
- Pay-setting controls: Limited
- Foreign activity oversight: Limited
- Grant itemization coverage: 96.8%; rating input score 97; 59th percentile among comparable filings
- Major donor itemization: Yes; rating input score 100
- Related-party transparency: Limited
Accountability
- Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
- Governance controls: 5 of 7 controls in place; rating input score 71
- Conflict-of-interest policy: Pass
- Whistleblower policy: Pass
- Document-retention policy: Pass
- CEO compensation review process: NotApplicable
- Other executive compensation review process: NotApplicable
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Missing
- Independent financial-statement audit: Fail
Sustainability
- Operating margin: -539.4%; rating input score 6; 6th percentile among comparable filings
- Total-asset coverage ratio: 9.84; rating input score 65; 65th percentile among comparable filings
- Liabilities to assets ratio: 0; rating input score 66; 66th percentile among comparable filings
- Officer compensation ratio: 0%; rating input score 58; 58th percentile among comparable filings
Growth
- Program expense growth: 9.7% per year; rating input score 100; 73rd percentile among comparable filings
- Revenue growth: -3% per year; rating input score 0; 46th percentile among comparable filings
- Asset growth: 9% per year; rating input score 100; 75th percentile among comparable filings
Details
- Where the money goes: 100% of revenue deployed · 99.6% of spending went to programs
- Governance: 11 of 11 board members independent · 5 of 7 filing controls reported
- Programs: 2 filed program accomplishments · $396K in reported program spending
- Leadership: top reported pay $0 · 12 people listed
- Consistency: 15 of 16 current checks pass · 1 finding to review
- Schedules: 4 filed schedules · includes major donors and grants
- Filing history: 10 filing years from 2015 to 2025
- Contacts: How to reach this organization
- Money network: 7 filed money-flow records
- Related organizations: 7 filed related-organization links
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Sustainability: Operating margin scored 6/100.
- High — Growth: Revenue growth scored 0/100.
- Review — Accountability: Governance controls: Independent financial-statement audit not reported.
- Review — Transparency & Controls: Domestic grant itemization did not reconcile in the filed values.
- Review — Sustainability: Officer compensation ratio scored 58/100.